Adoptive T-cell therapy for cancer: the era of engineered T cells
Open accessThe DOI matches its Crossref record; 133 of the 134 references it cites were found in a registry or an index.
Abstract
Tumors originate from a number of genetic events that deregulate homeostatic mechanisms controlling normal cell behavior. The immune system, devoted to patrol the organism against pathogenic events, can identify transformed cells, and in several cases cause their elimination. It is however clear that several mechanisms encompassing both central and peripheral tolerance limit antitumor immunity, often resulting into progressive diseases. Adoptive T-cell therapy with either allogeneic or autologous T cells can transfer therapeutic immunity. To date, genetic engineering of T cells appears to be a powerful tool for shaping tumor immunity. In this review, we discuss the most recent achievements in the areas of suicide gene therapy, and TCR-modified T cells and chimeric antigen receptor gene-modified T cells. We provide an overview of current strategies aimed at improving the safety and efficacy of these approaches, with an outlook on prospective developments.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“TCR-engineered T cells or CAR-engineered T cells increase the efficacy of the antitumor immune response (79).”
From Gut Microbiome as a Potential Factor for Modulating Resistance to Cancer Immunotherapy (2020) · cites this paper as [79]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407222 · Cited by 5,413
Chimeric antigen receptor–modified T cells in chronic lymphoid leukemia
Porter, D. L., Levine, B. L., Kalos, M., Bagg, A., & June, C. H. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103849 · Cited by 3,565
Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
Grupp, S. A., Kalos, M., Barrett, D., Aplenc, R., Porter, D. L., Rheingold, S. R., Teachey, D. T., Chew, A., Hauck, B., Wright, J. F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215134 · Cited by 3,509
Salgado, R., Denkert, C., Demaria, S., Sirtaine, N., Klauschen, F., Pruneri, G., Wienert, S., Van den Eynden, G., Baehner, F. L., Penault-Llorca, F., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdu450 · Cited by 3,113
Graft-versus-leukemia reactions after bone marrow transplantation
Horowitz, M., Gale, R., Sondel, P., Goldman, J., Kersey, J., Kolb, H., Rimm, A., Ringden, O., Rozman, C., & Speck, B. (1990) · Blood · doi:10.1182/blood.v75.3.555.555 · Cited by 2,774
Adoptive cell transfer as personalized immunotherapy for human cancer
Rosenberg, S. A., & Restifo, N. P. (2015) · Science · doi:10.1126/science.aaa4967 · Cited by 2,506
Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens
Gubin, M. M., Zhang, X., Schuster, H., Caron, E., Ward, J. P., Noguchi, T., Ivanova, Y., Hundal, J., Arthur, C. D., Krebber, W.-J., et al. (2014) · Nature · doi:10.1038/nature13988 · Cited by 1,974
A human memory T cell subset with stem cell–like properties
Gattinoni, L., Lugli, E., Ji, Y., Pos, Z., Paulos, C. M., Quigley, M. F., Almeida, J. R., Gostick, E., Yu, Z., Carpenito, C., et al. (2011) · Nature Medicine · doi:10.1038/nm.2446 · Cited by 1,974
Research works printed but not linked: 3
- C 2015 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.eji-journal.eu 15214141, 2015, 9, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/eji.201545552, Wiley Online Library on [09/08/2026]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License
- C 2015 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.eji-journal.eu 15214141, 2015, 9, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/eji.201545552, Wiley Online Library on [09/08/2026]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License Eur. J. Immunol. 2015. 45: 2457-2469 REVIEWS 2469 119
- Milan, Italy e-mail: chiara.bonini@hsr.it See all the ECI 2015 Reviews at http://onlinelibrary.wiley.com/journal/ 10.1002/(ISSN)1521-4141/homepage/eci2015.htm · doi:10.1002/(issn)1521-4141/homepage/eci2015.htm
Cited by
Passweg, J. R., Baldomero, H., Chabannon, C., Basak, G. W., de la Cámara, R., Corbacioglu, S., Dolstra, H., Duarte, R., Glass, B., Greco, R., et al. (2021) · Bone Marrow Transplantation · doi:10.1038/s41409-021-01227-8 · Cited by 429
for the European Society for Blood and Marrow Transplantation (EBMT), Passweg, J. R., Baldomero, H., Bader, P., Bonini, C., Duarte, R. F., Dufour, C., Gennery, A., Kröger, N., Kuball, J., et al. (2017) · Bone Marrow Transplantation · doi:10.1038/bmt.2017.34 · Cited by 395
The application of CAR-T cell therapy in hematological malignancies: advantages and challenges
Zhao, Z., Chen, Y., Francisco, N. M., Zhang, Y., & Wu, M. (2018) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2018.03.001 · Cited by 246
for the European Society for Blood and Marrow Transplantation (EBMT), Passweg, J. R., Baldomero, H., Chabannon, C., Basak, G. W., Corbacioglu, S., Duarte, R., Dolstra, H., Lankester, A. C., Mohty, M., et al. (2020) · Bone Marrow Transplantation · doi:10.1038/s41409-020-0826-4 · Cited by 187
for the European Society for Blood and Marrow Transplantation (EBMT), Passweg, J. R., Baldomero, H., Basak, G. W., Chabannon, C., Corbacioglu, S., Duarte, R., Kuball, J., Lankester, A., Montoto, S., et al. (2019) · Bone Marrow Transplantation · doi:10.1038/s41409-019-0465-9 · Cited by 173
Metadata
- Authors
- Bonini, C., & Mondino, A.
- Affiliations
- IRCCS Ospedale San Raffaele (IT)
- Corresponding author
- Bonini, Chiara
- Mondino, Anna
- Venue
- European Journal of Immunology
- Publisher
- Wiley
- Published
- 2015-08-21
- Volume
- 45
- Issue
- 9
- Pages
- 2457-2469
- ISSN
- 0014-2980 (ISSN-L)
- 1521-4141
- OpenAlex
- W1957268835
- Cited by
- 93
- References
- 134
- Citations by year
- 2026: 4 · 2025: 5 · 2024: 3 · 2023: 10 · 2022: 10 · 2021: 10 · 2020: 8 · 2019: 16 · 2018: 12 · 2017: 8 · 2016: 7
- FWCI
- 0.96
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- European Journal of Immunology (publishedVersion)
- PubMed (publishedVersion)
- Archivio Istituzionale della Ricerca - Università Vita-Salute San Raffaele (submittedVersion)
- Funders
- Associazione Italiana per la Ricerca sul Cancro (IG 11970 and IG 15883)
- Fifth Framework Programme (LSHC-CT-2005-018914 ATTACK)
- Topics
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- adoptive T cell therapy, engineered T cells, suicide gene therapy, chimeric antigen receptor T cells, antitumor immunity, tumor immune evasion, allogeneic T cells, autologous T cells
- MeSH terms
- Antigens, Neoplasm, Forecasting, Humans, Neoplasms, Receptors, Antigen, T-Cell, T-Lymphocytes, Genetic Therapy, Gene Expression, Immunotherapy, Adoptive, Genes, Transgenic, Suicide, Mutant Chimeric Proteins, Cell Engineering, Cell- and Tissue-Based Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.